KLRS — Kalaris Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-07-30.
Performance
Technicals
Others in Healthcare
Measured signals that fired on KLRS
| date | signal | measured base rate |
|---|---|---|
| 2026-05-22 | Cluster buy: three or more insiders insider | +0.63% over 21 days · t = 1.84 · n = 3,050 not distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-05-20 | Samsara BioCapital, L.P. 10% owner | Open-market purchase | 244.3K | 4.83 | 1.2M |
| 2026-05-20 | AKKARAJU SRINIVAS Director | Open-market purchase | 244.3K | 4.83 | 1.2M |
| 2026-05-20 | Samsara Opportunity Fund, L.P. 10% owner | Open-market purchase | 244.3K | 4.83 | 1.2M |
| 2026-05-20 | Samsara Opportunity Fund GP, LLC 10% owner | Open-market purchase | 244.3K | 4.83 | 1.2M |
| 2026-05-20 | Samsara BioCapital GP, LLC 10% owner | Open-market purchase | 244.3K | 4.83 | 1.2M |
| 2026-05-20 | Samsara BioCapital, L.P. 10% owner | Other Acquisition/Disposition | 14.9K | 0.00 | 0 |
| 2026-05-20 | Samsara BioCapital, L.P. 10% owner | Other Acquisition/Disposition | 66.9K | 0.00 | 0 |
| 2026-05-20 | AKKARAJU SRINIVAS Director | Other Acquisition/Disposition | 14.9K | 0.00 | 0 |
| 2026-05-20 | Samsara BioCapital GP, LLC 10% owner | Other Acquisition/Disposition | 66.9K | 0.00 | 0 |
| 2026-05-20 | Samsara BioCapital, L.P. 10% owner | Other Acquisition/Disposition | 4.5K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| SAMSARA BIOCAPITAL, LLC | 74.7M | 12.9M |
| RTW INVESTMENTS, LP | 7.5M | 1.3M |
| Paradigm Biocapital Advisors LP | 4.0M | 700.0K |
| Alyeska Investment Group, L.P. | 3.3M | 572.7K |
| Siren, L.L.C. | 2.5M | 435.8K |
| Ikarian Capital, LLC | 2.1M | 360.0K |
| Propel Bio Management, LLC | 1.7M | 295.8K |
| Kalehua Capital Management LLC | 1.6M | 271.2K |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.5M | 255.3K |
| RAYMOND JAMES FINANCIAL INC | 686.0K | 118.9K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Kalaris Therapeutics GAAP EPS of -$0.48 in-line · 2026-08-11
- Kalaris Therapeutics, Inc. (KLRS) filed form 8-K · 2026-08-11 · SEC EDGAR
Ask the AI about KLRS
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →